Toward a cure for lung cancer:important advances in operable non-small cell lung cancer  

推动可手术非小细胞肺癌走向治疗的重要研究进展

作　　者：Si-Yang Maggie Liu Guang-Ling Jie Yi-Long Wu 刘思阳;揭光灵;吴一龙(Department of Hematology,First Affiliated Hospital,Jinan University,Guangzhou 510632,China;Guangdong Lung Cancer Institute,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,Guangzhou 510080,China;School of Medicine,South China University of Technology,Guangzhou 510006,China)

机构地区：[1]Department of Hematology,First Affiliated Hospital,Jinan University,Guangzhou 510632,China [2]Guangdong Lung Cancer Institute,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,Guangzhou 510080,China [3]School of Medicine,South China University of Technology,Guangzhou 510006,China

出　　处：《Science Bulletin》2022年第14期1402-1405,共4页科学通报（英文版）

基　　金：supported by the Key Lab System Project of Guangdong Science and Technology Department,Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer(2017B030314120);Guangdong Provincial People’s Hospital Scientific Research Funds for Leading Medical Talents in Guangdong Province(KJ012019426);China Postdoctoral Science Foundation(2021M701422)。

摘　　要：Over the past 20 years,the discovery of genes driving non-small cell lung cancer(NSCLC)has intensified;today,NSCLC is divided into driven and non-driven populations.Targeted therapy and programmed cell death-1(PD-1)inhibitors have become the standard of care for advanced driven and non-driven NSCLC,respectively.

关 键 词：非小细胞肺癌 NSCLC LUNG 

分 类 号：R734.2[医药卫生—肿瘤]